The hypoxic tumor microenvironment suppresses anti-cancer immune responses by modulating multiple signaling pathways including, but not limited to, hypoxia-inducible factor (HIF-1) signaling.
Hypoxia has been shown through HIF-1 signaling to:
By delivering oxygen to the hypoxic tumor microenvironment, OMX reverses these effects and stimulates an immune attack on tumor cells resulting in tumor cell death.
Within minutes of a stroke, a severe reduction of blood flow and oxygen supply causes cell death in the part of the brain tissue surrounding the blocked blood vessel (black). In the immediate vicinity of the dead tissue is a hypoxic zone (green) - tissue that is severely deprived of oxygen and at risk of dying. If left untreated, the oxygen-deprived tissue will die, resulting in further impairments in speech, motor, and cognitive function. By restoring oxygen levels in brain tissue affected by stroke, Omniox’s drug candidate for stroke (OMX-IS) can delay or prevent this progressive neuronal death, saving brain tissue and preserving brain function.
In cardiovascular ischemia, such as during a heart attack or acute blood loss, hypoxia drives a vicious cycle in which the heart tissue is damaged, negatively affecting blood flow and reducing oxygen levels, and depriving all organ systems of oxygen. This in turn results in a number of complications, including reduced heart function, long-term neurological deficits, and organ failure. OMX-CV oxygenates the hypoxic heart tissue to break this cycle and preserve heart and other major organ function.